Invention Grant
- Patent Title: GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof
-
Application No.: US17046686Application Date: 2019-03-19
-
Publication No.: US11542336B2Publication Date: 2023-01-03
- Inventor: Cheng Zhang , Hua Zhang , Xiaofeng Wang , Chenjiang Yao , Yan Jiang , Liangliang Bi , Shuqian Jing
- Applicant: GMAX BIOPHARM LLC
- Applicant Address: CN Hangzhou
- Assignee: GMAX BIOPHARM LLC
- Current Assignee: GMAX BIOPHARM LLC
- Current Assignee Address: CN Hangzhou
- Agency: Jones Day
- Priority: CN201810316473.0 20180410
- International Application: PCT/CN2019/078674 WO 20190319
- International Announcement: WO2019/196603 WO 20191017
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/605
Abstract:
Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
Public/Granted literature
Information query
